Successful treatment of PASH syndrome with infliximab, cyclosporine and dapsone

Journal of the European Academy of Dermatology and Venereology

Volumn 29, Issue 11, 2015, Pages 2243-2247

  Staub, J ^a   Pfannschmidt, N ^b   Strohal, R ^b   Braun Falco, M ^d   Lohse, P ^c   Goerdt, S ^a   Leverkus, M ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Federal Academic Teaching Hospital   (Austria)

^c Institute of Laboratory Medicine and Human Genetics   (Germany)

^d UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; DAPSONE; INFLIXIMAB; ANTIINFECTIVE AGENT; DERMATOLOGICAL AGENT; IMMUNOSUPPRESSIVE AGENT;

ACNE; ADULT; CASE REPORT; CHROMOSOME 15Q; DERMATITIS; FEMALE; GENE MUTATION; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PYODERMA GANGRENOSUM; PYODERMA GANGRENOSUM ACNE SUPPURATIVE HIDRADENITIS SYNDROME; REVIEW; SKIN BIOPSY; SUPPURATIVE HIDRADENITIS; YOUNG ADULT; ACNE VULGARIS; COMBINATION DRUG THERAPY; HIDRADENITIS SUPPURATIVA; SYNDROME;

ACNE VULGARIS; ANTI-INFECTIVE AGENTS; CYCLOSPORINE; DAPSONE; DERMATOLOGIC AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HIDRADENITIS SUPPURATIVA; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLIXIMAB; PYODERMA GANGRENOSUM; SYNDROME; YOUNG ADULT;

EID: 84945246003     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.12765     Document Type: Review

References (20)

1. Braun-Falco M, Kovnerystyy O, Lohse P, Ruzicka T,. Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH)-A new autoinflammatory syndrome distinct from PAPA syndrome. J Am Acad Dermatol 2012; 66: 409-415.
2. Wise CA, Gillum JD, Seidman CE, Lindor NM, Stavros Bashiardes RV, Lovett M,. Mutations in CD2BP1 disrupt binding to PTPPEST and are responsible for PAPA syndrome, an autoinflammatory disorder. Hum Mol Gen 2002; 11: 961-969.
3. Stichweh DS, Punaro M, Pascual V,. Dramatic improvement of pyoderma gangrenosum with infliximab in a patient with PAPA Syndrome. Pediatr Dermatol 2005; 3: 262-265.
4. Bruzzese V,. Pyoderma gangrenosum, acne conglobata, suppurative hidradenitis, and axial spondyloarthritis-Efficacy of anti α tumor necrosis factor-therapy. J Clin Rheumatol 2012; 18: 413-415.
5. Marzano AV, Trevisan V, Gattorno M, Ceccherini I, De Simone C, Crosti C,. Pyogenic arthritis, pyoderma gangrenosum, acne, and hidradenitis suppurativa (PAPASH): a new autoinflammatory syndrome associated with a novel mutation of the PSTPIP1 gene. JAMA Dermatol 2013; 149: 762-764.
6. Demidowich AP, Freeman AF, Kuhns DB, et al,. Genotype, Phenotype, and Clinical Course in Five Patients With PAPA Syndrome (Pyogenic Sterile Arthritis, Pyoderma Gangrenosum, and Acne). Arthritis Rheum 2012; 64: 2022-2027.
7. Geusau A, Mothes-Luksch N, Nahavandi H, et al,. Identification of a homozygous PSTPIP1 mutation in a patient with a PAPA-like Syndrome Responding to Canakinumab Treatment. JAMA Dermatol 2013; 149: 209-215.
8. Jaeger T, Andres C, Grosber M, et al,. Pyoderma gangrenosum and concomitant hidradenitis suppurativa-rapid response to canakinumab (anti-IL-1). Eur J Dermatol 2013; 23: 408-410.
9. Koshelev MV, Garrison PA, Wright TS,. Concurrent hidradenitis suppurativa, inflammatory acne, dissecting cellulitis of the scalp, and pyoderma gangrenosum in a 16-year-old boy. Pediatr Dermatol 2014; 31: e20-e21.
10. van der Zee HH, de Winter K, van der Woude CJ, Prens EP,. The prevalence of hidradenitis suppurativa in 1093 patients with inflammatory bowel disease. Br J Dermatol 2014; 171: 673-675 doi: 10.1111/bjd.13002 [Epub ahead of print].
11. Miller J, Yentzer BA, Clark A, Jorizzo JL, Feldman SR,. Pyoderma gangrenosum: a review and update on new therapies. J Am Acad Dermatol 2010; 62: 9.
12. Wollina U, Haroske G,. Pyoderma gangrenosum. Curr Opin Rheumatol 2011; 23: 50-56.
13. Brooklyn TN, Dunnill MG, Shetty A, et al,. Infliximab for the treatment of pyoderma gangrenosum: a randomized, double blind, placebo controlled trial. Gut 2006; 33: 505-509.
14. Eaton PA, Callen JP,. Mycophenolate mofetil as therapy for pyoderma gangrenosum. Arch Dermatol 2009; 145: 781-785.
15. Hsiao JL, Antaya RJ, Berger T, Maurer T, Shinkai K, Leslie KS,. Hidradenitis suppurativa and concomitant pyoderma gangrenosum-A case series and literature review. Arch Dermatol 2010; 146: 1265-1270.
16. Ah-Weng A, Langtry A, Velangi S, Evans CD, Douglas WS,. Pyoderma gangrenosum associated with hidradenitis suppurativa. Clin Exp Dermatol 2005; 30: 669-671.
17. Garcia-Rabasco AE, Esteve-Martinez A, Zaragoza-Ninet V, Sanchez-Carazo JL, Alegre-de-Miquel V,. Pyoderma gangrenosum associated with hidradenitis suppurativa: a case report and review of the literature. Actas Dermosifiliogr 2010; 101: 717-721.
18. Revuz JE, Canoui-Poitrine F, Wolkenstein P, et al,. Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies. J Am Acad Dermatol 2008; 59: 596-601.
19. Crowley JJ, Mekkes JR, Zouboulis CC, et al,. Association of Hidradenitis Suppurativa Disease Severity with Increased Risk for Systemic Comorbidities. Br J Dermatol 2014; doi: 10.1111/bjd.13122 [Epub ahead of print].
20. Lukens JR, Kanneganti TD,. Beyond canonical inflammasomes: emerging pathways in IL-1-mediated autoinflammatory disease. Semin Immunopathol 2014; May 17 [Epub ahead of print].